Gene identified that could help prevent or delay onset of Alzheimer's disease

Boosting ABCC1 could lessen the production of plaque linked to Alzheimer's development

16-Apr-2021 - Findings of a study by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest that increasing expression of a gene known as ABCC1 could not only reduce the deposition of a hard plaque in the brain that leads to Alzheimer's disease, but might also prevent or ...

TGen study identifies potential genes associated with the most common form of liver damage

02-Sep-2015 - In a first-of-its-kind exploratory study, the Translational Genomics Research Institute (TGen) has identified a potential gene associated with the initiation of the most common cause of liver damage. Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver damage. In this study, ...

The Ben & Catherine Ivy Foundation contributes $10 million to TGen for brain cancer research

Arizona philanthropist Catherine (Bracken) Ivy keeps her focus on those diagnosed with brain cancer

17-Jul-2012 - The Ben & Catherine Ivy Foundation has awarded $10 million in grants for two brain cancer research projects at the Translational Genomics Research Institute (TGen).One $five-million-project is titled "Outliers in Glioblastoma Outcome: Moving the curve forward." This five-year investigation seeks ...

Arizona companies team up, providing quick development of cancer drugs

TGen Drug Development (TD2) and Flagship Biosciences offer combined oncology and pathology services for pharmaceutical and biotech clients

31-Jan-2011 - TGen Drug Development (TD2) and Flagship Biosciences today announced a strategic alliance that should help speed new drugs safely into human testing and quickly benefit cancer patients. TD2, based in Scottsdale, Ariz., provides drug development firms with expertise in moving promising laboratory ...

Rondaxe and TD2 form strategic drug development alliance

22-Feb-2010 - TGen Drug Development (TD2) and Rondaxe Enterprises announced a strategic alliance that will help emerging companies speed new high-quality treatments to cancer patients. Rondaxe, a drug development consulting company, helps emerging pharmaceutical and biotechnology companies navigate through all ...

TGen and Scottsdale Healthcare discover new 'pathways'

Computer simulations validate treatment targets for lung cancer

12-Oct-2009 - Using computer modeling, the Translational Genomics Research Institute and Scottsdale Healthcare have discovered lung cancer 'pathways' that could become targets for new drugs, according to a scientific paper inn the Journal of Thoracic Oncology . Dr. Glen Weiss, Director of Thoracic Oncology at ...

TGen and Washington University researchers discover new approach to treating endometrial cancer

Inhibitor turns 'off' receptors; stops the growth of endometrial tumors and kills cancer cells

03-Sep-2008 - Researchers at the Translational Genomics Research Institute (TGen) announced a new approach to treating endometrial cancer patients that not only stops the growth of tumors, but kills the cancer cells. In a potentially major breakthrough, TGen scientists and collaborators at Washington ...

SYGNIS acquires Amnestix Inc.

SYGNIS strengthens its position with access to discovery capabilities of the Translational Genomics Research Institute

10-Jun-2008 - SYGNIS Pharma AG announced that it has acquired privately-owned US biopharmaceutical company Amnestix Inc. As part of the acquisition, SYGNIS will gain access to a broad range of CNS projects within the world-renowned Translational Genomics Research Institute (TGen, Phoenix, AZ). SYGNIS will pay ...

Researchers Identify Genetic Mutation That May Alter Patients' Response to Cancer Therapeutics

Recurring mutation found in breast, colorectal and ovarian cancers

06-Jul-2007 - Researchers from Eli Lilly & Company and the Phoenix-based Translational Genomics Research Institute (TGen) announced finding a novel recurring mutation of the gene AKT1 in breast, colorectal and ovarian cancers. The altered form of AKT1 appears to cause tumor cell proliferation and may play a ...

Scan of Entire Human Genome Finds Unexpected New Clues on Lou Gehrig's Disease

04-Dec-2006 - A comprehensive scan of the human genome has identified more than 50 genetic abnormalities in people with sporadic amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), the Muscular Dystrophy Association (MDA) and the Translational Genomics Research Institute (TGEN) announced. The most ...